Speakers
Mariella Filbin
Pediatric Oncologist
Dana Farber Cancer Institute
Day One
Wednesday, January 19, 2022
12:15 pm | Developmental Pathways, Plasticity and Neural Regulation of Pediatric High-Grade Glioma
James Garner
Chief Executive Officer
Kazia Therapeutics
Day One
Wednesday, January 19, 2022
3:30 pm | Paxalisib In Glioblastoma – Key Learnings From A Phase II Study in Newly-Diagnosed Patients
Susan Chang
Professor Neurological Surgery
UCSF Weill Institute for Neurosciences
Day One
Wednesday, January 19, 2022
8:40 am | Impact of Molecular Classification of GBM on Clinical Trial Design and Analysis
Michael Lim
Professor & Chair Department of Neuro Surgery
Stanford University School of Medicine
Day Two
Thursday, January 20, 2022
12:10 pm | Mechanisms of Immunosuppression
David Louis
Pathologist-in-Chief
Massachusetts General Hospital
Day One
Wednesday, January 19, 2022
8:10 am | An Overview of the 2021 WHO Classification and Implications for Diffuse Glioma Diagnosis
Justin Lathia
Vice Chair
Cleveland Clinic
Day One
Wednesday, January 19, 2022
11:45 am | Sex Differences in the GBM Immune Response
Neil White
Investment Manager Health
Emerson Collective
Day Two
Thursday, January 20, 2022
10:40 am | Panel: It’s All in the Money – Funding Challenges & Opportunities in the GBM Space
Saiid Zarrabian
President & Chief Executive Officer
Kintara Therapeutics
Day One
Wednesday, January 19, 2022
2:30 pm | Role of Cytotoxic Agents in GBM
Dennis Brown
Chief Scientific Officer
Kintara Therapeutics
Alex Tendler
Chief Technology Officer
ExoProTher Medical
Day Two
Thursday, January 20, 2022
5:10 pm | Xenogeneic Corneal Epithelial Cells Derived Vesicles Containing P53 as a Novel GBM Therapy
Sheila Singh
Professor of Surgery
Mc Master University
Day Two
Thursday, January 20, 2022
3:10 pm | Targeting Clonal Heterogeneity In Treatment-Refractory GBM With Empiric Polytherapy
Rifaquat Rahman
Radiation Oncology
Dana Farber Cancer Institute
Day One
Wednesday, January 19, 2022
3:00 pm | Leveraging External Data for the Design and Analysis of Glioblastoma Trials
Christophe Queva
Chief Scientific Officer
Oncorus
Day Two
Thursday, January 20, 2022
2:10 pm | Optimization of an Oncolytic HSV-1 for the Treatment of Glioblastoma
Josh Rubin
Neuro-Oncologist
Washington University
Day One
Wednesday, January 19, 2022
11:15 am | Accounting for Cancer on the Spectrum in Drug Development
Jeffrey Skolnik
Vice President Clinical Development
Inovio
Day Two
Thursday, January 20, 2022
8:40 am | Inovio’s DNA Medicine for the Treatment of Glioblastoma
Amy Heimburger
Neurological Surgery
Northwestern Medical Group
Becky Bish
Head of Discovery & Preclinical Research
The Mark Foundation
Day One
Wednesday, January 19, 2022
1:45 pm | Panel: How Nonprofit Foundations Can Synergize With Biopharma to Catalyze New Product Development in GBM
Day Two
Thursday, January 20, 2022
10:40 am | Panel: It’s All in the Money – Funding Challenges & Opportunities in the GBM Space
Suzanne Forry
Program Director, Preclinical Therapeutics Grants Branch
National Cancer Institute
Day Two
Thursday, January 20, 2022
10:40 am | Panel: It’s All in the Money – Funding Challenges & Opportunities in the GBM Space
Jim Beach
Chief Operating Officer
Bexion Pharmaceuticals
Day Two
Thursday, January 20, 2022
1:40 pm | Leveraging the Lysosome to Treat Glioblastoma
Kirk Tanner
Chief Scientific Officer
National Brain Tumor Society
Day One
Wednesday, January 19, 2022
9:25 am | Panel: Why Are We Not Doing Better? An Open Discussion of the Limitations of Current Drug Development for GBM and Where the Field Can Improve
Day Two
Thursday, January 20, 2022
10:40 am | Panel: It’s All in the Money – Funding Challenges & Opportunities in the GBM Space
Joao Seixas
Chief Executive Officer
Targtex
Day Two
Thursday, January 20, 2022
4:10 pm | Novel Hydrogel-Based Localized Treatment For Glioblastoma
Adilia Hormigo
Professor of Neurology
The Tisch Cancer Institute
Day Two
Thursday, January 20, 2022
2:40 pm | STINGing GBM
John De Groot
Professor Neuro-Oncology
MD Anderson Cancer Center
Klaus Veitinger
Venture Partner
OrbiMed Advisors
Day Two
Thursday, January 20, 2022
10:40 am | Panel: It’s All in the Money – Funding Challenges & Opportunities in the GBM Space
Marnix Bosch
Chief Technology Officer
NorthWest Biotherapeutics
Day Two
Thursday, January 20, 2022
11:40 am | Immunotherapy of Brain Cancer: Past, Present and Future
Steve Kay
Professor of Neurology
Keck School of Medicine
Day Two
Thursday, January 20, 2022
4:40 pm | Targeting Circadian Clock Proteins in Glioblastoma
Ranjit Bindra
Professor, Therapeutic Radiology
Yale University School of Medicine
Day Two
Thursday, January 20, 2022
9:10 am | Targeting the DNA Damage Response in Glioma: Emerging New Concepts and Novel Directions
Patrick Wen
Director Neuro-Oncology
Dana Farber Cancer Institute
Day One
Wednesday, January 19, 2022
4:30 pm | RANO. 2.0 Update in Response Assessment for Glioblastomas
9:25 am | Panel: Why Are We Not Doing Better? An Open Discussion of the Limitations of Current Drug Development for GBM and Where the Field Can Improve
9:10 am | Why Are We Not Doing Better? Overview Of Limitations of Current Drug Development for GBM and Potential Improvements
Bob Dillman
Chief Medical Officer
AIVITA Biomedical
Day One
Wednesday, January 19, 2022
5:00 pm | AV-GBM-1 Patient-Specific Vaccines in Newly Diagnosed Primary Glioblastoma
Heinz Lubenau
Chief Executive Officer
VAXIMM
Day One
Wednesday, January 19, 2022
5:30 pm | Oral DNA Vaccination in Combination With Checkpoint Inhibitor In Recurrent Glioblastoma
Mike Goguen
Founder & Managing Partner
Two Bear Capital
Day Two
Thursday, January 20, 2022
10:40 am | Panel: It’s All in the Money – Funding Challenges & Opportunities in the GBM Space
Petra Hamerlik
Director
AstraZeneca
Day Two
Thursday, January 20, 2022
8:10 am | Targeting DNA Repair in Glioblastoma: New Era of Brain Penetrant Agents
Shwetal Mehta
COO
Ivy Brain Tumor Center
Day One
Wednesday, January 19, 2022
9:25 am | Panel: Why Are We Not Doing Better? An Open Discussion of the Limitations of Current Drug Development for GBM and Where the Field Can Improve
Kip Beardsley
CEO
OurBrainBank
Day One
Wednesday, January 19, 2022
10:00 am | Keeping the Passion Going, Harnessing the Passion of a Dynamic Founder
